• Profile
Close

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Journal of Hepatology Jun 13, 2019

Borgia SM, et al. - In patients with hepatitis C virus (HCV) infection with end-stage renal disease (ESRD) undergoing dialysis, researchers tested the safety and effectiveness of sofosbuvir/velpatasvir. Open-label sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks was given to 59 patients with genotype 1-6 HCV infection with ESRD undergoing hemodialysis or peritoneal dialysis in this phase 2, single-arm study. SVR12 was accomplished in 56 out of 59 patients in patients with ESRD undergoing dialysis; treatment with sofosbuvir/velpatasvir for 12 weeks was safe and effective. Headache, fatigue, nausea, and vomiting were the most common adverse events.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay